



(51) International Patent Classification:

A61N 5/06 (2006.01)

(21) International Application Number:

PCT/SG2019/050037

(22) International Filing Date:

22 January 2019 (22.01.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10201800633S 24 January 2018 (24.01.2018) SG

(71) Applicant: NATIONAL UNIVERSITY OF SINGAPORE [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG).

(72) Inventors: HO, John; c/o National University of Singapore, Faculty of Engineering / Department of Electrical and Computer Engineering, 21 Lower Kent Ridge Road, Singapore 119077 (SG). ZHANG, Yong; c/o National University

of Singapore, Faculty of Engineering / Department of Biomedical Engineering, 21 Lower Kent Ridge Road, Singapore 119077 (SG). BANSAL, Akshaya; c/o National University of Singapore, Faculty of Engineering / Department of Biomedical Engineering, 21 Lower Kent Ridge Road, Singapore 119077 (SG). YANG, Fengyuan; c/o National University of Singapore, Faculty of Engineering / Department of Electrical and Computer Engineering, 21 Lower Kent Ridge Road, Singapore 119077 (SG). TIAN, Xi; c/o National University of Singapore, Faculty of Engineering / Department of Electrical and Computer Engineering, 21 Lower Kent Ridge Road, Singapore 119077 (SG).

(74) Agent: LINDSAY, Jonas Daniel; Marks & Clerk Singapore LLP, Tanjong Pagar, P O Box 636, Singapore 910816 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: PHOTODYNAMIC THERAPY DEVICES, SYSTEMS AND METHODS




Figure 10

(57) Abstract: Wirelessly powered photodynamic therapy devices are disclosed and systems and methods using such devices are also disclosed. In an embodiment, a photodynamic therapy system comprises: an implantable illumination device comprising a light source configured to emit light having a spectrum which overlaps with an absorption peak of an absorption target and a receiver antenna coupled to the light source and configured to extract power from a radiofrequency power signal incident on the implantable illumination device; and a transmitter comprising an antenna, a powering module configured to generate a drive signal which causes the antenna to generate the radiofrequency power signal, and a dosimetry module coupled to the antenna and configured to detect a radiofrequency signal backscattered from the implantable illumination device and determine an indication of the power extracted by the implantable illumination device from the radiofrequency signal backscattered from the implantable illumination device.

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *of inventorship (Rule 4.17(iv))*

**Published:**

— *with international search report (Art. 21(3))*

## PHOTODYNAMIC THERAPY DEVICES, SYSTEMS AND METHODS

### TECHNICAL FIELD

- 5 The present disclosure relates to photodynamic therapy and in particular to photodynamic therapy devices, systems and methods in which power is wirelessly transmitted to an implantable illumination device.

### BACKGROUND

10

Advances in understanding and engineering light-tissue interactions have enabled a class of targeted therapies with unmatched spatiotemporal resolution. Photodynamic therapy (PDT) is a clinical example in which light-sensitive drugs known as photosensitizers are selectively activated by light, producing reactive oxygen species (ROS) which can be used to kill malignant cells. Other emerging treatments include photothermal therapy and photobiomodulation. Clinical application of PDT, however, has been hindered by the low penetration of light through biological tissue, which limits the therapeutic depth to less than a centimeter, even at near-infrared wavelengths. Currently, light delivery into deeper tissue regions relies on optical fibers inserted through surgery or endoscopy, but their incompatibility with long-term implantation allows only a single light dose to be delivered. This limitation in light delivery precludes the use of PDT for long-term therapy in order to suppress tumor recurrence or to tailor the dose to the tumor response.

### 25 SUMMARY OF THE INVENTION

According to a first aspect of the present disclosure a photodynamic therapy system comprises: an implantable illumination device comprising a light source configured to emit light having a spectrum which overlaps with an absorption peak of an absorption target and a receiver antenna coupled to the light source and configured to extract power from a radiofrequency power signal incident on the implantable illumination device; and a transmitter comprising an antenna, a powering module configured to generate a drive signal which causes the antenna to generate the radiofrequency power signal, and a dosimetry module coupled to the antenna and

configured to detect a radiofrequency signal backscattered from the implantable illumination device and determine an indication of the power extracted by the implantable illumination device from the radiofrequency signal backscattered from the implantable illumination device.

5

In an embodiment, the light source comprises a first light emitting device configured to emit light having a first wavelength and a second light emitting device configured to emit light having a second wavelength different from the first wavelength.

10 In an embodiment, the implantable illumination device comprises a printed circuit board and a plurality of electronic components mounted on the printed circuit board and wherein the receiver antenna comprises a helical coil having a plurality of turns around the printed circuit board.

15 In an embodiment, the implantable illumination device comprises a planar substrate and wherein the light source comprises a plurality of light emitting devices arranged on the planar substrate. The receiver antenna may comprise a conductive loop formed on the planar substrate. The planar substrate may be formed from a flexible material.

20

In an embodiment the receiver antenna is configured to provide a resonance for a range of frequencies including the radiofrequency power signal.

25 In an embodiment, the implantable illumination device is encapsulated in an encapsulation material.

In an embodiment, wherein the implantable illumination device comprises at least one flap formed from the encapsulation material.

30 In an embodiment, the implantable illumination device comprises a regulator circuit configured to reduce variations emitted light intensity from the light source due to changes in power extracted by the implantable illumination device.

In an embodiment the regulator circuit comprises a clamp circuit. In an embodiment, the clamp circuit comprises a zener diode.

5 In an embodiment, the radiofrequency signal backscattered from the implantable illumination device is a harmonic of the radiofrequency power signal.

10 In an embodiment, the transmitter is configured to control the radiofrequency power control signal based on the indication of the power extracted by the implantable illumination device to control an illumination dose provided by the implantable illumination device.

In an embodiment, the transmitter is configured to provide an indication of the indication of the power extracted to a user.

15 In an embodiment, the radio frequency power signal has a frequency in the range 1 to 5 GHz.

20 In an embodiment the transmitter further comprises a controller configured to modify the drive signal to spatially focus the radiofrequency power signal on the implantable illumination device.

25 In an embodiment, the transmitter operates in either the electromagnetic near-field (close range, <1 cm distance) or midfield (deep in tissue, >1 cm) ranges and spatially shapes the radio-frequency field in order to focus energy on the device.

In some embodiments, the absorption target is a photosensitizer. In some embodiments, the absorption target is a light transducer selected to emit light having a spectrum that overlaps with an absorption peak of a photosensitizer.

30 According to a second aspect of the present disclosure, an implantable illumination device comprises a light source configured to emit light having a spectrum which overlaps with an absorption peak of an absorption target and a receiver antenna coupled to the light source and configured to extract power from a radiofrequency power signal incident on the implantable illumination device.

According to a third aspect of the present disclosure transmitter for a photodynamic therapy system, comprises: an antenna, a powering module configured to generate a drive signal which causes the antenna to generate a radiofrequency power signal to wirelessly provide power to an implantable illumination device, and a dosimetry module coupled to the antenna and configured to detect a radiofrequency signal backscattered from the implantable illumination device and determine an indication of the power extracted by the implantable illumination device from the radio frequency signal backscattered from the implantable illumination device.

According to a fourth aspect of the present disclosure a method of treating a tumor in a patient comprises implanting an implantable illumination device proximate to or within the tumor; administering a photosensitizer to the patient; and transmitting a radiofrequency power signal to the implantable illumination device.

In an embodiment the method further comprises receiving a backscattered radiofrequency signal from the implantable illumination device and determining a light dose applied to the tumor from the received backscattered signal.

In an embodiment the method further comprises adjusting the radiofrequency power signal to control the light dose applied to the tumor.

In an embodiment, adjusting the radiofrequency power signal comprises adjusting a polarization, or focus location of the radiofrequency power signal and / or changing a location or orientation of a transmitter of the radiofrequency power signal.

In an embodiment, the method further comprises administering a light transducer material to the patient, the light transducer material being selected to emit light having a spectrum that overlaps with an absorption peak of the photosensitizer.

## BRIEF DESCRIPTION OF THE DRAWINGS

In the following, embodiments of the present invention will be described as non-limiting examples with reference to the accompanying drawings in which:

Figure 1 shows a schematic of a photodynamic therapy method;

Figure 2 shows an image of the implantable illumination device;

Figure 3 shows a schematic of the implantable illumination device;

5 Figure 4 shows a circuit diagram of the implantable illumination device;

Figures 5a to 5i show the assembly of the implantable illumination device;

Figure 6 is a graph showing the emission spectrum of LEDs in an implantable illumination device and the absorption spectrum of the photosensitizer;

10 Figures 7a and 7b are images of the light distribution of violet light, and red light, respectively around the implantable illumination device on a synthetic tissue slab;

Figures 8a and 8b shows the results of a numerical simulation of optical irradiance around a device embedded in homogenous tumor-like tissue;

Figure 9 shows images of the penetration of light emitted by an implantable illumination device through tumors of different volume;

15 Figure 10 shows a schematic of a system comprising the implantable illumination device and a transmitter for generating a radiofrequency power signal;

Figure 11 is a graph showing the maximum radiant power as a function of depth of the device;

20 Figure 12 shows the change in emitted radiant power as a function of the output power of the transmitter for a device with and without a clamping circuit;

Figure 13 is a graph showing heating of tumor tissue under light exposure;

Figure 14 shows a schematic of the transmitter of the photodynamic therapy system;

25 Figure 15 is a graph showing the power of the third harmonic signal as a function of power level of the radiofrequency drive signal received by the implantable illumination device;

Figures 16a to 16c show computed tomography (CT) reconstructions of the radio-frequency transmitter and device implanted an adult pig model;

Figure 17 shows the results for ROS production in Ce6 solution in the region surrounding the device;

30 Figures 18a to 18d illustrate test configurations for investigating ROS production;

Figure 19 shows the results showing cell viability for the test configurations shown in Figures 18a to 18d;

Figure 20 shows apoptosis for the test configurations shown in Figures 18a to 18d;

Figures 21a to 21g show florescence images of treated cells and control cells;

Figures 22a to 22e show computed tomography reconstructions of representative mice in five groups

Figures 23a to 23e show stained tumor tissue sections corresponding to the test groups shown in Figures 22a to 22e

5 Figure 24 shows normalized tumor volume as a function of time during a monitoring period;

Figure 25 shows body weight over a treatment period;

Figure 26 shows stained sections of tumor tissue following a single round of treatment using either wireless light delivery or laser light delivery;

10 Figure 27 shows stained sections of healthy tissues adjacent to the tumor;

Figure 28 shows normalized fluorescence results for protoporphyrin IX as a photosensitizer;

Figure 29 shows normalized fluorescence results for zinc phthalocyanine as a photosensitizer;

15 Figures 30A to 30F illustrate results demonstrating device biosafety;

Figure 31 shows an implantable illumination device for treatment of a brain tumor;

Figure 32 shows the implantable illumination device for treatment of a brain tumor;

Figures 33A and 33B are graphs showing production of reactive oxygen species (ROS) by Ce6 when illuminated using a wireless illumination device emitting red

20 (660nm) light, and UV/violet (405nm) light respectively;

Figure 34 shows the cell kill in C6 rat glioma due to UV light triggered photodynamic therapy using the photosensitizer Ce6;

Figure 35 shows a schematic circuit diagram of a near infra-red (NIR) light emitting implantable illumination device; and

25 Figure 36 shows reactive oxygen species production triggered by up-converted blue light from up-conversion nanoparticles illuminated with a NIR light emitting device.

## DETAILED DESCRIPTION

30 The present disclosure relates to a wireless photonic approach to photodynamic therapy (PDT) that enables on-demand light activation of photosensitizers deep in the body. A system comprising an implantable photonic device and a wireless powering system delivers therapeutic doses of light into tissues inaccessible by direct illumination. The miniaturized (30 mg, 15 mm<sup>3</sup>) dimensions of the device

allows its direct implantation at the target site, where a specialized radio-frequency system wirelessly powers the device and monitors the light dosing rate.

Figure 1 shows a schematic of the PDT method for treating a lesion. First, the implantable illumination device 110 is inserted through the skin 102 of a patient 104 near the target lesion 106. Because of its small dimensions, the implantable illumination device 110 is compatible with minimally invasive implantation during standard clinical procedures such as incisional biopsy or during surgical tumor resection to combat tumor recurrence. Second, a photosensitizer 108 is administered to the patient 104. The photosensitizer 108 is by itself harmless. Finally, the implantable illumination device 110 is wirelessly powered, with a radiofrequency signal 120, which causes the implantable illumination device 110 to illuminate the target lesion 106 with light 122 having a wavelength or spectrum of wavelengths selected to activate the photosensitizer 108. The illumination results in the localized production of cytotoxic reactive oxygen species (ROS) from the photosensitizer 108 that directly kill malignant cells, damage the tumor microvasculature, and/or stimulate the host immune response. By spatially and temporally controlling the light dose, the therapy can be tailored for maximum efficacy and minimum side effects.

In some embodiments, as is described in more detail below with reference to Figures 35 and 36, a light transducer material, such as up-conversion nanoparticles (UCNPs) is administered to the patient in addition to the photosensitizer. The light transducer material is selected to emit light which activates the photosensitizer in response to absorbing light of a different wavelength. The use of such a light transducer material allows treatment of larger tumors since wavelength of light emitted by the implantable illumination device can be selected as, for example near infra-red (NIR) which has a greater penetration depth than light in the visible or ultraviolet range of the spectrum.

Figure 2 shows an image of the implantable illumination device. The inset shows the device illuminating an explanted tumor. As shown in Figure 2, the implantable illumination device 110 is encapsulated with an encapsulation material 112 which is optically transparent such as medical-grade silicone. Flaps 114 are formed from the encapsulation material to control the orientation of the implantable illumination

device 110 and to facilitate fixation using sutures. As shown in Figure 2, the largest diameter of the implantable illumination device 110 is around 3 mm.

Figure 3 shows a schematic of the implantable illumination device. As shown in Figure 3, the implantable illumination device 110 comprises a custom two-sided printed circuit board (PCB) 130. Two surface mount LEDs 132 are mounted on the PCB 130. As will be described in more detail below, the LEDs 132 are selected to provide an optical emission spectrum to activate the photosensitizer. In this example, the LEDs 132 provide red (660nm) and violet (400nm) emissions respectively. The implantable illumination device 110 further comprises a three-turn helical coil 134 for receiving radio-frequency energy, and a rectifier for alternating current to direct current conversion formed from surface mount capacitors 138 and radio-frequency Schottky diodes 136. The helical coil 134 is formed from enameled wire. The electrical components are mounted on the PCB 130 using lead-free soldering materials. The helical coil is arranged to maximize the fraction of the device volume that it occupies and therefore maximize the collected power by the coil.

As shown in the inset of Figure 3, the implantable illumination device 110 is encapsulated with an encapsulation material 112 which may comprise Polydimethylsiloxane (PDMS) and a silicone elastomer. Flaps 114 are formed from the encapsulation material.

Figure 4 shows a circuit diagram of the implantable illumination device. As shown in Figure 4, the LEDs 132 are connected in series. A rectifier 140 formed from the capacitors and diodes connects the helical coil 134 to the LEDs 132. The rectifier 140 acts to convert the alternating current signal received by the helical coil 134 to a direct current which powers the LEDs 132.

The dimensions of the helical coil 134 are selected such that the combined circuit exhibits a resonance in the operating frequency range, which also enhances power collection.

Figures 5a to 5i show the assembly of the implantable illumination device. As shown in Figure 5a, the PCB 130 was laser cut to the exact size. Then, as shown in Figure

5b, the LEDs 132 were mounted using micro-soldering under a microscope. On the reverse side shown in Figure 5c, the diodes and capacitors were mounted as shown in Figure 5d. As shown in Figures 5e and 5f, the helical coil 134 was formed around the device by wrapping enameled wire three times around the assembled PCB and soldering the two ends on designed pads.

As shown in Figure 5g, multiple devices 110 were encapsulated in a 3-D printed mold 150 by pouring PDMS, degassing in a vacuum chamber for one hour, and curing in a forced convection oven. As shown in Figures 5h and 5i, the encapsulated devices were removed from the mold and coated with a thin layer of rapid curing, biocompatible silicone 112 to enhance electrical isolation and surface smoothness. Encapsulation materials should be transparent to radio-frequency fields and light, including but not limited to silicone, glass, ceramics, and epoxies. As described above, flaps 114 are formed from the encapsulation material or the silicone coating.

Figure 6 is a graph showing the emission spectrum of LEDs in an implantable illumination device and the absorption spectrum of the photosensitizer. The exemplary implantable illumination device described herein is configured to be used with the photosensitizer Chlorin e6 (Ce6). As shown in Figure 6, the photosensitizer emission spectrum 610 has peaks at around 400nm and 660nm. Thus the violet LED having an emission spectrum with a peak at around 400nm and the red LED having an emission spectrum with a peak at around 660nm are selected so that the peaks of the emission spectrum from the two LEDs matches the peaks of the absorption spectrum of the photosensitizer. Ce6 is a clinically approved photosensitizer widely used for cancer treatment. It will be appreciated that the general configuration can be used with any photosensitizer, with the emission spectrum of the LEDs selected to overlap with the activation spectrum of the photosensitizer.

Figures 7a and 7b are images of the light distribution of violet light, and red light, respectively around the implantable illumination device on a synthetic tissue slab. As shown in Figures 7a and 7b, the irradiance contours approximate a sphere with center offset in the direction of emission at both wavelengths owing to light scattering. The direction of emission in Figures 7a and 7b is upwards towards the top of the

page. The emission is directional, indicating control of the orientation of the LEDs is important, although optical scattering limits the spatial selectivity of the light delivery.

Figures 8a and 8b shows the results of a numerical simulation of optical irradiance around a device embedded in homogenous tumor-like tissue. Figure 8a shows  $\Phi_e$  which is the emitted radiant power, or equivalently the light dosing rate. The solid white contour 810 shows a  $1\text{mW}/\text{cm}^2$  irradiance contour. The simulations estimate that at a total radiant power of  $1.3\text{ mW}$ , the irradiance reaches  $1\text{ mW}/\text{cm}^2$  at a radius of  $4\text{ mm}$  for red and  $1.2\text{ mm}$  for violet light in the direction of maximum intensity.

Figure 8b shows light dose contours of a  $2\text{ J}/\text{cm}^2$  does for exposure times of 1 to 30 minutes. As shown in Figure 8b, At the radius mentioned above ( $4\text{ mm}$  for red and  $1.2\text{ mm}$  for violet light in the direction of maximum intensity) the resulting optical exposure of  $2\text{ J}/\text{cm}^2$  is reached over a period of 30 min, which is sufficient to activate most photosensitizers.

Figure 9 shows images of the penetration of light emitted by an implantable illumination device through tumors of different volume. The upper images in Figure 9 show the tumors which have increasing diameters from left to right from approximately  $2\text{mm}$  to approximately  $10\text{mm}$ . The lower images show the illuminated tumors. The device used to provide the illumination in the images in Figure 9 has a radiant power of  $1.3\text{mW}$ . As illustrated in Figure 9, the device emits light when wirelessly powered in a radio-frequency field with sufficient radiant power to fully illuminate a tumor volume about  $5\text{mm}$  in diameter (the third image from the left hand side).

Figure 10 shows a schematic of a system comprising the implantable illumination device and a transmitter for generating a radiofrequency power signal. The transmitter 1020 comprises a powering module 1030 and a dosimetry module. The transmitter 1020 also comprises an antenna 1050 which is coupled to the powering module 1030 and the dosimetry module 1040 by a coupler 1060.

In operation, the powering module 1030 drives antenna with a radio-frequency signal having a frequency  $f_{\text{RF}}$  between 1 to 5 GHz. Transmitters were designed for

operation both in the electromagnetic near-field (close range, <1 cm distance) and midfield (deep in tissue, >1 cm) ranges. As shown in Figure 10, the transmitter 1020 wirelessly powers the implantable illumination device 110 which is at a depth of  $d$  with a signal having a frequency  $f_{RF}$ . The backscattered third harmonic signal having a frequency  $3f_{RF}$  is measured to establish the emitted radiant power  $\Phi_e$  of the implantable illumination device 110.

The dosimetry module 1040 controls the light dose delivered to the target region. The control by the dosimetry module 1040 is based on the measurement of harmonic signals including the third harmonic signal having a frequency  $3f_{RF}$  backscattered during wireless powering. Wireless powering for a prescribed light doing rate was established in two steps: (1) while holding the transmit power constant, the transmitter position was adjusted until the measured harmonic backscatter was maximized (compensating for potential misalignment between the transmitter and receiver); (2) while holding the transmitter position constant, the transmit power was tuned such that the light emission was set to the desired level using the dosimetry module 1040.

The antenna 1050 may allow spatial shaping of the radiofrequency power signal. For example, the antenna 1050 may comprise a plurality of excitation ports and the transmitter 1020 may comprise a controller configured to adjust a phase and / or amplitude delivered to the excitation ports to allow spatial shaping of the electromagnetic field of the radiofrequency power signal. Examples of such transmitters are provided in US Patent Application Publication US2016/0339256.

Figure 11 is a graph showing the maximum radiant power as a function of depth of the device. The graph shown in Figure 11 was generated using data for a device in tissue simulating water. The graph shows the maximum radiant power  $\Phi_e$  when the device was powered in a midfield configuration with an output power  $P_{RF}$  from the transmitter of 2W. Figure 11 shows that in the midfield configuration, the maximum radiant power that can be delivered by the device exceeds 1 mW at a 4 cm depth in water at a transmit power of 2 W. The target power of 1.3mW is reached for depths of around 48mm.

The sensitivity of light delivery to variations in wireless powering can be further reduced by incorporating a clamping circuit to limit light emission beyond the target rate. This is illustrated in Figure 12.

5 Figure 12 shows the change in emitted radiant power as a function of the output power of the transmitter for a device with and without a clamping circuit. The inset of Figure 12 shows an example of the clamping circuit.

10 As shown in the inset of Figure 12, the clamping circuit 1210 comprises a zener diode 1220 connected in parallel with the two LEDs and the output of the rectifier 140. Figure 12 shows data points for an unclamped device 1230 (an implantable illumination device without a clamping circuit) and for a clamped device 1240 (an implantable illumination device with a clamping circuit – as shown in the inset of Figure 12). As illustrated in Figure 12, across a twofold increase or decrease in  
15 power level around the operating point (radiant power, 1.3 mW), the clamping circuit reduces the variation in light output from 70% to less than 10%.

Figure 13 is a graph showing heating of tumor tissue under light exposure. Figure 13 shows the change in tissue temperature against time for different exposure powers.  
20 The curves in Figure 13 show powers of  $\Phi_e = 10\text{mW}$  (A);  $\Phi_e = 4.5\text{mW}$  (B); and  $\Phi_e = 1.3\text{mW}$  (C). The lines in the graph show the mean change in temperature; the shaded areas around the lines represent the standard deviation (calculated using  $n=3$ ). Thermal measurements show that the delivery of the light dose at the 1.3 mW rate limits the heat generated in tumor tissue to less than  $1^\circ\text{C}$  over 2 min irradiation  
25 after which the temperature reaches steady state, which is well below thresholds for tissue damage.

These estimates are consistent with the experiments in explanted tumor tissues shown in Figure 9, which show the penetration of light through about 5 mm thickness.  
30 For the selected emission wavelengths, the blood volume fraction of the tissue is important in determining the range of light delivery; the therapeutic volume depends on the type of tumor mass and may be greater for less vascularized tumors. The wireless powering system is capable of achieving these levels of radiant power deep in tissue-like material. In the midfield configuration, the maximum radiant power that

can be delivered by the device exceeds 1 mW at a 4 cm depth in water at a transmit power of 2 W. The performance of the system meets the requirements for light delivery to tumors deep in the body and enables illumination of volumes up to ~130 mm<sup>3</sup> (assuming a hemisphere volume of radius 4 mm), about 8 times the volume of the device.

Figure 14 shows a schematic of the transmitter of the photodynamic therapy system. As described above with reference to Figure 10, the transmitter comprises a powering module, a dosimetry module, an antenna and a coupler. Figure 14 illustrates the functions of these modules in more detail. As shown in Figure 14, the power module comprises a signal generator 1032 which generates a radiofrequency signal and a power amplifier 1034 which amplifies the radiofrequency signal to provide a drive signal for the antenna 1050. A controller 1044 which in this implementation is a computer running LABVIEW software controls the signal generator 1032 to control the power  $P_{RF}$  of the radiofrequency signal.

The dosimetry module is formed from a spectrum analyzer 1042 which is coupled to the antenna and configured to measure the power  $P_{3H}$  of the third harmonic signal which is backscattered from the implantable illumination device 110 to the antenna 1050. The spectrum analyzer 1042 provides an indication of the power  $P_{3H}$  of the third harmonic signal to the controller 1044 which determines the light dose and controls the power of the drive signal.

The coupler which couples the powering module and the dosimetry module to the antenna 1050 is formed from a directional coupler 1062 which provides the output of the power amplifier 1034 to the antenna 1050 and also couples the antenna to the spectrum analyzer 1042. A low-pass filter 1064 is provided between the power amplifier 1034 and the directional coupler 1062 to remove signals with a frequency greater than the radiofrequency drive signal. A high pass-filer 1066 is provided between the directional coupler 1062 and the spectrum analyzer 1042 which prevents the drive signal from the power amplifier 1034 from reaching the spectrum analyzer 1042 to allow the third harmonic signal to be isolated.

Figure 15 is a graph showing the power of the third harmonic signal as a function of power level of the radiofrequency drive signal received by the implantable illumination device. Figure 15 shows the power of the third harmonic signal received by the antenna normalized to the respective power levels at the  $\Phi_e = 1.3\text{mW}$  operating point. The derivative  $dP_{PH}/dP_{RF}$ . As shown in Figure 15, the harmonic power abruptly increases around LED threshold, from which the target dose rate can be established by a predetermined offset. As the device is powered near activation threshold, the non-linearity of the LEDs results in an abrupt increase in the harmonic signal level, which is detected and used as an absolute reference for establishing the desired light dosing rate. The backscattered harmonic signal also facilitates the placement of the transmitter on the body surface in order to optimize the transfer efficiency and avoid misalignment between transmitter and receiver.

To illustrate that the implantable illumination devices could be powered through thick tissue at depths relevant to human scales, ROS production studies were conducted in an adult pig model.

Figures 16a to 16c show computed tomography (CT) reconstructions of the radio-frequency transmitter and device implanted an adult pig model. As shown in Figure 16a, the device was implanted in the abdomen and ROS detection was carried out in the area surrounding the device. As shown in Figure 16b, the transmitter (Source) was placed on the skin, and as shown in Figure 16c, the device was placed 5.1 cm deep, on the liver surface.

Figure 17 shows the results for ROS production in Ce6 solution in the region surrounding the device. As shown in Figure 17, wireless light delivery by the device activated Ce6 and caused significant ROS production when powered through the thick intervening tissue. Figure 17 shows the mean and the error bar represent the standard deviation ( $n=3$  per group). The control (No Ce6) was a control solution with no Ce6 and the test solution was a solution containing  $5\mu\text{M}$  Ce6.

Using Ce6-incubated murine bladder cancer cells, ROS production was further validated against red laser irradiation, the current clinical standard, in two configurations: (i) cells directly exposed to the radio-frequency/laser source, and (ii)

cells placed under thick (3 cm) porcine tissue, simulating light delivery to deep tissue regions.

Figures 18a to 18d illustrate test configurations for investigating ROS production.

- 5 Figure 18a illustrates a test configuration in which laser light is directly incident on the MB49 cells and Figure 18 illustrates a test configuration in which the laser light travels through 3cm of tissue. The laser illumination was carried out with the following intensity  $37.5 \text{ mW/cm}^2$ ,  $4 \text{ J/cm}^2$ . Figure 18c illustrates a test configuration in which a wirelessly powered implantable device is powered without intervening tissue.
- 10 For this configuration near-field (NF) wireless powering was used. Figure 18d illustrates a test configuration in which a wirelessly powered implantable device is powered without though 3cm of tissue. For this configuration mid-field (MF) wireless powering was used.
- 15 Figure 19 shows the results showing cell viability for the test configurations shown in Figures 18a to 18d. Change in cell viability (MTS assay) following 20 min of irradiation in the above light delivery configurations is shown. The light dosing rate was  $1.3 \text{ mW}$  throughout. Groups include untreated cells, cells exposed to Ce6 alone, cells exposed to light alone and cells incubated with Ce6 and exposed to light from a
- 20 laser or the device with or without intervening tissue section. As can be seen from Figure 19, illumination with the wirelessly powered implantable device resulted in significantly reduced cell viability for both the direct and the through tissue scenarios. Laser illumination was effective at reducing cell viability in the direct scenario but not in the through tissue scenario. Specifically, wireless light delivery resulted in nearly
- 25 80% cell kill in both configurations ( $P= 0.0027$  direct and  $P=0.0039$  through thick tissue), whereas laser illumination obstructed by thick tissue did not result in a significant difference in cell viability ( $P=0.178$ ).

- Cell death could be attributed to apoptosis, a widely accepted mechanism for PDT-mediated cytotoxicity. Figure 20 shows apoptosis for the test configurations shown in
- 30 Figures 18a to 18d. Apoptosis index (TUNEL assay) including positive and negative controls from the assay are shown. As shown in Figure 20 there is high apoptosis for both wireless scenarios, but only for the direct laser scenario. In the through

tissue laser configuration, the apoptosis is low and comparable to the untreated control scenario.

Figures 21a to 21g show florescence images of treated cells and control cells.

5     Figures 21a and 21b show cells treated following incubation with Ce6 and illuminated with respectively, the direct laser configuration and, the though tissue laser configuration. Figures 21c and 21d show cells treated following incubation with Ce6 and illuminated with respectively, the near field (direct) wireless configuration and, the though tissue (mid field) wireless configuration. Figures 21e to 21g show  
10     control scenarios. Figure 21e shows untreated cells. Figure 21f shows cells subjected to Ce6 only and Figure 21g shows cells subjected to light only. The results were obtained from a fluorogenic, cell-permeable ROS sensor (Image-iT live Green ROS).

15     As can be seen from the results described above, wireless illumination with the device resulted in increased signal both in close proximity to the radio-frequency source and through thick tissue. In contrast, laser illumination was effective only under direct irradiation: obstruction of the beam with thick tissue resulted in insignificant ROS-induced fluorescence. Controls consisting of light, radio-frequency  
20     field, or Ce6 exposure alone also did not result in significant ROS production. In all cases, significant cell death resulted from oxidative stress. These results demonstrate successful light-based targeting of malignant cells in regions inaccessible by direct laser illumination.

25     We next demonstrated the efficacy of the light delivery system for cancer PDT in C57 BL/6 mice. The cancer model enables the therapeutic effect of the light dose to be tested in vivo, although the small size of the animals does not reproduce the depth of target region.

30     Figures 22a to 22e show computed tomography reconstructions of representative mice in five groups. The images were taken 13 days after first treatment. Figure 22a shows an untreated mouse, Figure 22b shows a mouse treated with Ce6 only, Figure 22c shows a mouse with an illumination device implanted at the location indicated by the white arrow, but without activation or treatment with Ce6. Figure 22d

shows a mouse with an illumination device implanted at the location indicated by the white arrow which was activated with an radiofrequency signal, and the mouse was not treated with Ce6. Figure 22e shows a mouse with an illumination device implanted at the location indicated by the white arrow which was activated with an radiofrequency signal, which was treated with Ce6.

Figures 23a to 23e show stained tumor tissue sections from each group described above with reference to Figures 22a to 22e. DAPI (dark grey) shows cell nuclei and TUNEL (light grey) staining indicates apoptosis.

Figure 24 shows normalized tumor volume as a function of time during the monitoring period. Treatments were administered on Day 3 (T1) and Day 9 (T2) with a light dose of 1.3 mW over 30 min. Graphs show mean  $\pm$  s.d. (n=5 per group).

Figure 25 shows body weight over the treatment period. As mentioned above with reference to Figure 24, were administered on Day 3 (T1) and Day 9 (T2).

The light dose was set to the same level (1.3 mW, 30 min) as used in the in vitro experiments. Devices were implanted in the interstitial space around a solid tumor grown to 4-6 mm diameter from MB49 bladder cancer cells subcutaneously injected into the hind region. After a recovery period, PDT was performed by intratumoral injection of Ce6 followed 4 hours later by wireless delivery of the light dose. Photosensitizers administered intratumorally have been shown to be retained in tumors for several hours, which is sufficient for the duration of the treatment. A second round of treatment was administered 7 days after the first, demonstrating ease of light delivery over long time scales. Control groups were left untreated; received Ce6 injections only, received sham devices only, or given light doses using functional devices without Ce6 injection.

Monitoring of the tumor volume as a function of time revealed suppression, and in some cases complete regression, of tumors in the treatment group compared to control groups. Wireless delivery of light dose alone did not significantly affect tumor growth, indicating that the treatment efficacy was not due to the mild thermal effect of light and/or radio-frequency field exposure. Monitoring of tumor volume ended 13

days after first treatment, beyond which tumors in the majority of the mice from control groups either reached ethical size limits or were ulcerated. Across all groups, mice were otherwise healthy and did not show appreciable weight loss. Resection and histological examination (cryosectioning and TUNEL staining) of tumors revealed a significantly greater population of apoptotic cells in the treatment group compared to control groups, indicating that photodynamic activity is the likely mechanism for tumor destruction. Tumor volumes cleared by PDT at the prescribed light dose are consistent with light transport calculations and measurements.

We compared the therapy to PDT by direct laser illumination, the current clinical standard, by histological examination of the tissue following a single round of treatment.

Figure 26 shows stained sections of tumor tissue following a single round of treatment using either wireless light delivery (wireless illumination) or laser light (660 nm) delivery (direct illumination).

Figure 27 shows stained sections of healthy tissues adjacent to the tumor. The white lines labelled "T.B." indicates a tissue boundary.

Tumor-bearing mice were injected intratumorally with Ce6 and administered either the prior light dose using the wireless device or using a red laser (660 nm) collimated to a 5-mm diameter spot. In both cases, explanted tumor tissues showed comparable apoptosis, but tissues sampled from regions adjacent to the tumor did not show significant damage as assessed by TUNEL staining. Thermal measurements show that radio-frequency field exposure induces less than 2°C increase in skin temperature after 4 min of operation and was less than laser illumination. These results suggest that PDT by wireless light delivery does not result in increased damage to healthy tissues compared to current clinical standards. ...

The system can be adapted for use with other photosensitizers. As an example, direct LED illumination of zinc phthalocyanine (ZnPc) and protoporphyrin IX (PpIX), two other clinically used photosensitizers with an absorption peak near 660 nm, also resulted in comparable levels of ROS in vitro.

Figure 28 shows normalized fluorescence results for protoporphyrin IX as a photosensitizer.

- 5 Figure 29 shows normalized fluorescence results for zinc phthalocyanine as a photosensitizer.

The selection of LEDs with emission wavelengths tuned to match the absorption peaks can further enhance PDT.

10

- Figures 30A to 30F illustrate results demonstrating device biosafety. Figure 30A shows confocal fluorescence microscopy images of MB49 (cancer) and HEK293T (non-cancer) cells grown on the device for 3 days. The grey fluorescence (calcein ex/em 488/520 nm) indicates live cells and the white arrows (PI, ex/em 488/635 nm) indicate dead cells. Control cells were incubated without the device. Figure 30B shows viability analysis of MB49 and HEK293T cells. Figure 30C shows Histological analyses of tissues around device implanted for 3 weeks. Tissues were stained for alpha smooth muscle actin ( $\alpha$ -SMA) in addition to H&E staining (scale bar 100 $\mu$ m). Control tissues were obtained from non-implanted mice. Figures 30D and 30E illustrate Fibrinogen and Complement C3 concentration in plasma from implanted (device) and non-implanted mice (control) measured by ELISA. Figure 30F shows the number of functional devices following submersion in phosphate-buffered solution (PBS) and cell culture media at 37°C. Graphs show mean  $\pm$  s.d. (n=3 per group).

25

- Potential clinical targets of our wireless PDT approach include hepatocellular carcinomas (liver tumors) or glioblastomas (brain tumors), where PDT currently provides promising outcomes compared to conventional treatment, but has been hindered by the inaccessibility of the target region to light. An example of a wireless implantable illumination device for treatment of brain tumors is described below.

30

Figure 31 shows an implantable illumination device for treatment of a brain tumor. As shown in Figure 31, the wireless implantable illumination device 3110 is a thin, flexible device, which comprises mesh of light emitting diode (LEDs). This allows the

wireless implantable illumination device 3110 to be implanted in the narrow confines beneath the skull of the subject. The wireless implantable illumination device 3110 is implanted close to the glioblastoma 3120 and as described above, light emitted from the wireless implantable illumination device 3110 activates a photosensitizer 3130 in the vicinity of the glioblastoma 3120.

Figure 32 shows the implantable illumination device shown in Figure 31. As shown in Figure 32, the implantable illumination device 3110 is formed from on a substrate 3210. The substrate 3210 is formed from a flexible material such as polyimide. The substrate 3210 is circular and a receiver antenna 3220 is formed as circular loop of copper on the substrate 3210 around the edge. A rectifier 3230 which comprises a plurality of diodes and capacitors is coupled to two ends of the receiver antenna 3220. It is noted that a gap is formed between the two ends of the circular loop of the receiver antenna 3220. The receiver antenna 3220 is connected across the alternating current (AC) input of the rectifier 3230. A plurality of light emitting diodes (LEDs) 3240 are connected in parallel across the direct current (DC) output of the rectifier 3230. A resistor 3250 is connected in series with each of the LEDs 3240.

The implantable illumination device 3110 shown in Figure 32 may be encapsulated in an encapsulation material in a similar manner to the device described above with reference to Figures 3 to 5. The arrangement of LEDs may be varied, for example pairs of red and violet LEDs may be arranged on the device or other combinations of LEDs may be arranged on the device.

The implantable illumination device 3110 shown in Figure 32 may be used with a transmitter of a wireless power signal such as that described above with reference to Figure 10.

Depending on the absorption spectrum of the photosensitizer used and the size of the tumor, the devices can be customized to emit a suitable light wavelength. The photosensitizer Ce6 (chlorin e6) has a strong absorption peak at 405nm and a weaker one at 660nm. Using LED meshes that emit either 405nm or 660nm light, the activation of the photosensitizer and generation of reactive oxygen species (ROS) was demonstrated. This is shown in Figure 33A and 33B.

Figure 33A is a graph showing production of reactive oxygen species (ROS) by Ce6 when illuminated using a wireless illumination device emitting red (660nm) light. Figure 33B is a graph showing production of reactive oxygen species (ROS) by Ce6  
5 when illuminated using a wireless illumination device emitting UV/violet (405nm) light.

From a comparison of Figures 33A and 33B, it can be seen that ROS yield is higher when UV/violet light is used. The 405nm light was more effective than the 660nm light in ROS generation owing to the stronger absorption peak of Ce6 at the 405nm  
10 wavelength.

Figure 34 shows the cell kill in C6 rat glioma due to UV light triggered photodynamic therapy (PDT) using the photosensitizer Ce6. From Figure 34, it can be seen that PDT triggered by UV/violet light emitting devices resulted in about 80% cell death of  
15 c6 rat glioma cells *in vitro*.

In the visible range (400-700nm) of the spectrum, the maximum depth penetration through tissue is less than 5mm, even when using red light. For shorter wavelengths such as UV light, this reduces to about 1mm. To treat larger tumors using PDT,  
20 longer wavelengths such as those in the near infrared range (NIR) are needed. These wavelengths can be used in conjunction with NIR to visible light transducers like upconversion nanoparticles (UCNP) to extend the range of PDT.

Figure 35 shows a schematic circuit diagram of a near infra-red (NIR) light emitting implantable illumination device. The implantable illumination device 3500 comprises  
25 a receiver antenna 3510 which is connected across the AC input of a rectifier circuit 3520. A NIR LED 3530 is connected across the DC output of the rectifier circuit 3520. The NIR LED 3530 emits light having a wavelength of 980nm. The rectifier circuit 3520 comprises four diodes and two capacitors. Additional NIR LEDs may be  
30 connected in parallel with the NIR LED 3530.

Figure 36 shows reactive oxygen species (ROS) production triggered by up-converted blue and red light emitted from up-conversion nanoparticles with an NaYF<sub>4</sub>(sodium yttrium fluoride) matrix doped with Yb<sup>3+</sup>(Ytterbium)/Er<sup>3+</sup>(Erbium) ions,

when illuminated with a NIR light emitting device. As shown in Figure 36 for currents of 30mA and above a significant increase in ROS production occurs.

5 We have demonstrated a wireless implantable photonic device that achieves therapeutic light delivery for cancer PDT. The operation of the device deep in the body is enabled by a radio-frequency system for wireless powering and monitoring of the light dose. As proof of concept, we wirelessly activated photosensitizers in situ in a porcine model of tissue and suppressed tumor activity in vivo in a murine cancer model by delivering light doses for PDT. The versatility of light delivery enabled by  
10 this approach overcomes the depth limitation of conventional PDT and extends its spatiotemporal precision to regions not directly accessible to light.

Potential clinical targets for which our approach could provide advantages include hepatocellular carcinomas or glioblastomas, where PDT currently provides promising  
15 outcomes compared to conventional treatment, but has been hindered by the inaccessibility of the target region to light. The versatility of light delivery allows light doses to be delivered over long time scales in a programmable and repeatable manner, and could potentially enable the therapies to be tailored in real-time.

20 Whilst the foregoing description has described exemplary embodiments, it will be understood by those skilled in the art that many variations of the embodiments can be made within the scope and spirit of the present invention.

## CLAIMS:

## 1. A photodynamic therapy system comprising:

an implantable illumination device comprising a light source configured to emit light having a spectrum which overlaps with an absorption peak of an absorption target and a receiver antenna coupled to the light source and configured to extract power from a radiofrequency power signal incident on the implantable illumination device; and

a transmitter comprising an antenna, a powering module configured to generate a drive signal which causes the antenna to generate the radiofrequency power signal, and a dosimetry module coupled to the antenna and configured to detect a radiofrequency signal backscattered from the implantable illumination device and determine an indication of the power extracted by the implantable illumination device from the radiofrequency signal backscattered from the implantable illumination device.

2. A photodynamic therapy system according to claim 1, wherein the light source comprises a first light emitting device configured to emit light having a first wavelength and a second light emitting device configured to emit light having a second wavelength different from the first wavelength.

3. A photodynamic therapy system according to claim 1 or claim 2, wherein the implantable illumination device comprises a printed circuit board and a plurality of electronic components mounted on the printed circuit board and wherein the receiver antenna comprises a helical coil having a plurality of turns around the printed circuit board.

4. A photodynamic therapy system according to claim 1 or claim 2, wherein the implantable illumination device comprises a planar substrate and wherein the light source comprises a plurality of light emitting devices arranged on the planar substrate.

5. A photodynamic therapy system according to claim 4, wherein the receiver antenna comprises a conductive loop formed on the planar substrate.

6. A photodynamic therapy system according to claim 4 or 5, wherein the planar substrate is formed from a flexible material.
7. A photodynamic therapy system according to any preceding claim, wherein the receiver antenna is configured to provide a resonance for a range of frequencies including the radiofrequency power signal.
8. A photodynamic therapy system according to any preceding claim, wherein the implantable illumination device is encapsulated in an encapsulation material.
9. A photodynamic therapy system according to claim 8, wherein the implantable illumination device comprises at least one flap formed from the encapsulation material.
10. A photodynamic therapy system according to any preceding claim, wherein the implantable illumination device comprises a regulator circuit configured to reduce variations emitted light intensity from the light source due to changes in power extracted by the implantable illumination device.
11. A photodynamic therapy system according to claim 10, wherein the regulator circuit comprises a clamp circuit.
12. A photodynamic therapy system according to claim 11, wherein the clamp circuit comprises a zener diode.
13. A photodynamic therapy system according to any preceding claim, wherein the radiofrequency signal backscattered from the implantable illumination device is a harmonic of the radiofrequency power signal.
14. A photodynamic therapy system according to any preceding claim, wherein the transmitter is configured to control the radiofrequency power control signal based on the indication of the power extracted by the implantable illumination device to control an illumination dose provided by the implantable illumination device.

15. A photodynamic therapy system according to any preceding claim, wherein the transmitter is configured to provide an indication of the indication of the power extracted to a user.
16. A photodynamic therapy system according to any preceding claim, wherein the radio frequency power signal has a frequency in the range 1 to 5 GHz.
17. A photodynamic therapy system according to any preceding claim, wherein the transmitter further comprises a controller configured to modify the drive signal to spatially focus the radiofrequency power signal on the implantable illumination device.
18. A photodynamic therapy system according to any preceding claim, wherein the absorption target is a photosensitizer.
19. A photodynamic therapy system according to any preceding claim, wherein the absorption target is a light transducer selected to emit light having a spectrum that overlaps with an absorption peak of a photosensitizer.
20. An implantable illumination device comprising a light source configured to emit light having a spectrum which overlaps with an absorption peak of an absorption target and a receiver antenna coupled to the light source and configured to extract power from a radiofrequency power signal incident on the implantable illumination device.
21. An implantable illumination device according to claim 20, wherein the light source comprises a first light emitting device configured to emit light having a first wavelength and a second light emitting device configured to emit light having a second wavelength different from the first wavelength.
22. An implantable illumination device according to claim 20 or claim 21, further comprising a printed circuit board and a plurality of electronic components mounted

on the printed circuit board and wherein the receiver antenna comprises a helical coil having a plurality of turns running around the printed circuit board.

23. An implantable illumination device according to claim 20 or claim 21, further comprising a planar substrate and wherein the light source comprises a plurality of light emitting devices arranged on the planar substrate.

24. An implantable illumination device according to claim 23, wherein the receiver antenna comprises a conductive loop formed on the planar substrate.

25. An implantable illumination device according to claim 23 or 24, wherein the planar substrate is formed from a flexible material.

26. An implantable illumination device according to any one of claims 20 to 25, wherein the receiver antenna is configured to provide a resonance for a range of frequencies including the radiofrequency power signal.

27. An implantable illumination device according to any one of claims 20 to 26, wherein the implantable illumination device is encapsulated in an encapsulation material.

28. An implantable illumination device according to claim 27, wherein the implantable illumination device comprises at least one flap formed from the encapsulation material.

29. An implantable illumination device according to any one of claims 20 to 28, wherein the implantable illumination device comprises a regulator circuit configured to reduce variations emitted light intensity from the light source due to changes in power extracted by the implantable illumination device.

30. An implantable illumination device according to claim 29, wherein the regulator circuit comprises a clamp circuit.

31. An implantable illumination device according to claim 30, wherein the clamp circuit comprises a zener diode.
32. An implantable illumination device according to any one of claims 20 to 31 wherein the radio frequency power signal has a frequency in the range 1 to 5 GHz.
33. An implantable illumination device according to any one of claims 20 to 32, wherein the absorption target is a photosensitizer.
34. An implantable illumination device according to any one of claims 20 to 32, wherein the absorption target is a light transducer selected to emit light having a spectrum that overlaps with an absorption peak of a photosensitizer.
35. A transmitter for a photodynamic therapy system, the transmitter comprising: an antenna, a powering module configured to generate a drive signal which causes the antenna to generate a radiofrequency power signal to wirelessly provide power to an implantable illumination device, and a dosimetry module coupled to the antenna and configured to detect a radiofrequency signal backscattered from the implantable illumination device and determine an indication of the power extracted by the implantable illumination device from the radiofrequency signal backscattered from the implantable illumination device.
36. A transmitter for a photodynamic therapy system according to claim 35, configured to control the radiofrequency power control signal based on the indication of the power extracted by the implantable illumination device to control an illumination dose provided by the implantable illumination device.
37. A transmitter for a photodynamic therapy system according to claim 35 or claim 36 wherein the transmitter is configured to provide an indication of the indication of the power extracted to a user.
38. A transmitter for a photodynamic therapy system according to any one of claims 35 to 37, wherein the radio frequency power signal has a frequency in the range 1 to 5 GHz.

39. A transmitter for a photodynamic therapy system according to any one of claims 35 to 38, wherein the radiofrequency signal backscattered from the implantable illumination device is a harmonic of the radiofrequency power signal.

40. A transmitter for a photodynamic therapy system according to any one of claims 35 to 39, further comprising a controller configured to modify the drive signal to spatially focus the radiofrequency power signal on the implantable illumination device.

41. A method of treating a tumor in a patient, the method comprising:  
implanting an implantable illumination device according to any one of claims 20 to 34 proximate to or within the tumor;  
administering a photosensitizer to the patient; and  
transmitting a radiofrequency power signal to the implantable illumination device.

42. A method according to claim 41, further comprising receiving a backscattered radiofrequency signal from the implantable illumination device and determining a light dose applied to the tumor from the received backscattered signal.

43. A method according to claim 42, further comprising adjusting the radiofrequency power signal to control the light dose applied to the tumor.

44. A method according to claim 43, wherein adjusting the radiofrequency power signal comprises adjusting a polarization, or focus location of the radiofrequency power signal and / or changing a location or orientation of the a transmitter of the radiofrequency power signal.

45. A method according to any one of claims 41 to 44, further comprising administering a light transducer material to the patient, the light transducer material being selected to emit light having a spectrum that overlaps with an absorption peak of the photosensitizer.

1/20




Figure 1




Figure 2

2/20




Figure 3




Figure 4

3/20




Figure 5

4/20




Figure 6




Figure 7a

Figure 7b

5/20




Figure 8a




Figure 8b




Figure 9

6/20




Figure 10




Figure 11

7/20




Figure 12




Figure 13

8/20




Figure 14




Figure 15

9/20




Figure 16




Figure 17

10/20




Figure 18




Figure 19




Figure 20

11/20




Figure 21

12/20




Figure 22




Figure 23




Figure 24




Figure 25

14/20




Figure 26




Figure 27

15/20




Figure 28




Figure 29




Figure 30

17/20




Figure 31




Figure 32




Figure 33A




Figure 33B

19/20




Figure 34




Figure 35




Figure 36

# INTERNATIONAL SEARCH REPORT

International application No.

**PCT/SG2019/050037**

## A. CLASSIFICATION OF SUBJECT MATTER

**A61N 5/06 (2006.01)**

According to International Patent Classification (IPC)

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPODOC/WPI/FAMPAT/IEEE/CAPLUS/BIOSIS/MEDLINE/EMBASE: wireless, photodynamic therapy, PDT, light therapy, implant, radiofrequency, coil, antenna, RF signal, backscattering, reflected, harmonic, wireless power transmission, WPT and related terms

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                    | Relevant to claim No. |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| P,X       | BANSAL A. ET AL, In vivo wireless photonic photodynamic therapy. <i>PNAS</i> , 13 February 2018, Vol. 115, No. 7, pages 1469-1474<br>[Retrieved on 2019-03-21] <DOI: 10.1073/PNAS.1717552115><br>Whole document       | 1-45                  |
| X         | US 2010/0305666 A1 (LOU S.L. ET AL) 2 December 2010<br>Whole document, particularly para. [0011], [0015], [0036]; Fig. 1A, 1B, 3A                                                                                     | 20-34, 41, 45         |
| X         | US 2014/0128943 A1 (ROGERS G.S. & HILL S.L.) 8 May 2014<br>Whole document, particularly para. [0007], [0022], [0023], [0028]-[0030], [0035] [0063]; Table 3; Fig. 1A                                                  | 20-34, 41, 45         |
| X         | WO 2017/004531 A1 (THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS & WASHINGTON UNIVERSITY IN ST. LOUIS) 5 January 2017<br>Whole document, particularly para. [0143], [0199]-[0201]; Fig. 20A, 26; claims 33 & 54 | 20-34                 |

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\*Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21/03/2019 (day/month/year)

Date of mailing of the international search report

10/04/2019 (day/month/year)

Name and mailing address of the ISA/SG

**IPOS** Intellectual Property Office of Singapore  
51 Bras Basah Road  
#01-01 Manulife Centre  
Singapore 189554

Email: pct@ipos.gov.sg

Authorized officer

Chen Xiuli (Dr)

IPOS Customer Service Tel. No.: (+65) 6339 8616

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SG2019/050037

**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category* | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                                                                                                                                                                                         | Relevant to claim No. |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X         | MONTGOMERY K.L. ET AL, Wirelessly powered, fully internal optogenetics for brain, spinal and peripheral circuits in mice. <i>Nature Methods</i> , 17 August 2015, Vol. 12, pages 969-974<br>[Retrieved on 2019-03-21] <DOI: 10.1038/NMETH.3536><br>Whole document, particularly page 970, left col. para. 4; Online methods, Implant construction; Supplementary Fig. 3 & 4                                                                                                                | 20-34                 |
| X         | PARK S. ET AL, Soft, stretchable, fully implantable miniaturized optoelectronic systems for wireless optogenetics. <i>Nat Biotechnol.</i> , 1 December 2015, Vol. 33, No. 12, pages 1280-1286<br>(NIH Public Access Author Manuscript in PMC)<br>[Retrieved on 2019-03-21 from <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880021/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880021/</a> ] <DOI: 10.1038/NBT.3415><br>Whole document, particularly page 2, para. 2; Fig. 1 | 20-34                 |
| P,X       | TIAN X. ET AL, Control of wireless power transfer to a bioelectronic device by harmonic feedback. <i>AIP Advances</i> , 12 September 2018, Vol. 8, No. 095308, pages 1-8<br>[Retrieved on 2019-03-21] <DOI: 10.1063/1.5030600><br>Whole document                                                                                                                                                                                                                                           | 20-40                 |
| X         | WO 2013/025632 A1 (STIMWAVE TECHNOLOGIES INCORPORATED) 21 February 2013<br>Whole document, particularly page 2, lines 2-6, 14-18, page 8, line 6, page 12, lines 21-22, page 13, lines 6-7, 10-12, 16-18, page 14, lines 13-15, page 25, lines 7-10, page 40, page 48, lines 5-7                                                                                                                                                                                                           | 35, 37-40             |
| A         | US 2017/0224248 A1 (ZOU Y. ET AL) 10 August 2017<br>Whole document, particularly para. [0026]- [0028], [0031], [0041]                                                                                                                                                                                                                                                                                                                                                                      | 35-40                 |
| A         | LUCKY S.S. ET AL, Nanoparticles in Photodynamic Therapy. <i>Chemical Reviews</i> , 20 January 2015, Vol. 115, No. 4, pages 1990-2042<br>[Retrieved on 2019-03-21] <DOI: 10.1021/cr5004198 ><br>Section 5.3.4; Tables 3-4                                                                                                                                                                                                                                                                   | -                     |

# INTERNATIONAL SEARCH REPORT

International application No.

**PCT/SG2019/050037**

## **Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## **Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please refer to Supplemental Box (Continuation of Box No. III).

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☒ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest** ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.

**PCT/SG2019/050037**

## **Supplemental Box** **(Continuation of Box No. III)**

This International Searching Authority found multiple inventions in this international application, as follows:

Group 1: Claims 1-19 relate to a photodynamic therapy system comprising an implantable illumination device comprising a light source and a receiver antenna coupled to the light source as well as a transmitter comprising an antenna, a powering module configured to generate a drive signal which causes the antenna to generate a radiofrequency power signal incident on the implantable illumination device and a dosimetry module coupled to the antenna and configured to detect a radiofrequency signal backscattered from the implantable illumination device.

Group 2: Claims 20-34 and 41-45 relate to an implantable illumination device system comprising a light source and a receiver antenna coupled to the light source or a method of treating a tumor involving implanting this implantable illumination device.

Group 3: Claims 35-40 relate to a transmitter *suitable for* a photodynamic therapy system comprising an antenna, a powering module configured to generate a drive signal which causes the antenna to generate a radiofrequency power signal to wirelessly provide power to an implantable illumination device and a dosimetry module coupled to the antenna and configured to detect a radiofrequency signal backscattered from the implantable illumination device.

Please refer to **Box No. IV** of Written Opinion of The International Searching Authority (Form PCT/ISA/237) for detailed explanation.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/SG2019/050037**

*Note: This Annex lists known patent family members relating to the patent documents cited in this International Search Report. This Authority is in no way liable for these particulars which are merely given for the purpose of information.*

| <b>Patent document<br/>cited in search report</b> | <b>Publication date</b> | <b>Patent family<br/>member(s)</b>                        | <b>Publication date</b>                |
|---------------------------------------------------|-------------------------|-----------------------------------------------------------|----------------------------------------|
| US 2010/0305666 A1                                | 02/12/2010              | CN 101375790 A<br>WO 2009/030109 A1                       | 04/03/2009<br>12/03/2009               |
| US 2014/0128943 A1                                | 08/05/2014              | WO 2014/074690 A1                                         | 15/05/2014                             |
| WO 2017/004531 A1                                 | 05/01/2017              | US 2018/0192952 A1                                        | 12/07/2018                             |
| WO 2013/025632 A1                                 | 21/02/2013              | US 2014/0336727 A1<br>EP 2741810 A1<br>US 2013/0066400 A1 | 13/11/2014<br>18/06/2014<br>14/03/2013 |
| US 2017/0224248 A1                                | 10/08/2017              | WO 2017/139136 A1<br>EP 3413794 A1                        | 17/08/2017<br>19/12/2018               |